Publication: Evaluation of intravenous fosfomycin disodium dosing regimens in critically ill patients for treatment of carbapenem-resistant enterobacterales infections using monte carlo simulation
15
Issued Date
2020-09-01
Resource Type
ISSN
20796382
Other identifier(s)
2-s2.0-85091088225
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antibiotics. Vol.9, No.9 (2020), 1-14
Suggested Citation
Pannee Leelawattanachai, Thitima Wattanavijitkul, Taniya Paiboonvong, Rongpong Plongla, Tanittha Chatsuwan, Sang Usayaporn, Wichit Nosoongnoen, Preecha Montakantikul Evaluation of intravenous fosfomycin disodium dosing regimens in critically ill patients for treatment of carbapenem-resistant enterobacterales infections using monte carlo simulation. Antibiotics. Vol.9, No.9 (2020), 1-14. doi:10.3390/antibiotics9090615 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/58967
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Evaluation of intravenous fosfomycin disodium dosing regimens in critically ill patients for treatment of carbapenem-resistant enterobacterales infections using monte carlo simulation
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. There are limited intravenous fosfomycin disodium (IVFOS) dosing regimens to treat carbapenem-resistant Enterobacterales (CRE) infections. This study aimed to use Monte Carlo simulation (MCS) for evaluation of IVFOS dosing regimens in critically ill patients with CRE infections. The dosing regimens in critically ill patients with various creatinine clearance were evaluated with MCS using minimum inhibitory concentration (MIC) distributions of fosfomycin against CRE clinical isolates in Thailand and the 24 h area under the plasma drug concentration–time curve over the minimum inhibitory concentration (AUC0-24/MIC) of ≥21.5 to be a target for IVFOS. The achieved goal of the probability of target attainment (PTA) and a cumulative fraction of response (CFR) were ≥90%. A total of 129 non-duplicated CRE clinical isolates had MIC distributions from 0.38 to >1024 mg/L. IVFOS 8 g every 8 h, 1 h, or 4 h infusion, could achieve approximately 90% PTA of AUC0-24/MIC target to treat CRE infections with MICs ≤ 128 mg/L. According to PTA target, an IVFOS daily dose to treat carbapenem-resistant Escherichia coli based on Clinical Laboratory Standards Institute (CLSI) breakpoints for urinary tract infections and one to treatment for CRE infections based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were 16 g/day and 8 g/day, respectively. All dosing regimens of IVFOS against CRE achieved CFR ≤ 70%. This study proposes the IVFOS dosing regimens based on CLSI and EUCAST breakpoints for the treatment of CRE infections. However, further clinical studies are needed to confirm the results of these findings.